Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: which class of drugs should be preferable for patients with cardiovascular pathology?
- Authors: Stolov S.V.1,2, Privalov K.A.1
-
Affiliations:
- Saint Petersburg Institute of Medical Experts
- North-Western State Medical University named after I.I. Mechnikov
- Issue: Vol 13, No 4 (2021)
- Pages: 31-46
- Section: Reviews
- URL: https://journals.eco-vector.com/vszgmu/article/view/89729
- DOI: https://doi.org/10.17816/mechnikov89729
Cite item
Abstract
The article presents a comparative analysis on the effectiveness of two classes of drugs — angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin II type 1 receptor blockers (ARB II) for patients with cardiovascular diseases: arterial hypertension, heart failure, coronary heart disease, ischemic brain disease. The advantage of ACE inhibitors over ARB II in reducing the risk of general and cardiac mortality, myocardial infarction, cerebral strokes, chronic heart failure, chronic kidney disease has been established. The positive effect of ACE inhibitors on the course of a new coronavirus infection is also demonstrated. The mechanisms of action of both classes of drugs are proposed for discussion, which substantiate the advantage of ACE inhibitors over ARB II from the standpoint of pathophysiology in relation to controlling major cardiovascular risks.
Full Text

About the authors
Sergey V. Stolov
Saint Petersburg Institute of Medical Experts; North-Western State Medical University named after I.I. Mechnikov
Email: sv100lov@gmail.com
ORCID iD: 0000-0002-3431-1224
SPIN-code: 5492-2429
MD, Dr. Sci. (Med.), Professor
Russian Federation, 11/12 B. Sampsonievsky Ave., Saint-Petersburg, 194044; Saint-PetersburgKonstantin A. Privalov
Saint Petersburg Institute of Medical Experts
Author for correspondence.
Email: kostus2004@list.ru
ORCID iD: 0000-0002-8917-3332
SPIN-code: 5323-5968
Russian Federation, 11/12 B. Sampsonievsky Ave., Saint-Petersburg, 194044
References
- Catalá-López F, Macías Saint-Gerons D, González-Bermejo D. Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses. PLOS Med. 2016;13(3):e1001971. doi: 10.1371/journal.pmed.1001971
- Wang K, Hu J, Luo T, et al. Effects of Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality and renal outcomes in patients with diabetes and albuminuria: a systematic review and meta-analysis. Kidney Blood Press Res. 2018;43(3):768–779. doi: 10.1159/000489913
- Vremennye metodicheskie rekomendacii profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19). Versiya 12 (21.09.2021). (In Russ.)
- Stabil’naya ishemicheskaya bolezn’ serdca. Klinicheskie rekomendacii 2020. Rossijskoe kardiologicheskoe obshchestvo (RKO). (In Russ.). doi: 10.15829/1560-4071-2020-4076
- Mareev VYu, Fomin IV, Ageev FT, et al. Russian heart failure society, Russian society of cardiology. Russian scientific medical society of internal medicine guidelines for heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiya. 2018;58(65):8–158. (In Russ.). doi: 10.18087/cardio.2475
- Kobalava ZD, Konradi AO, Nedogoda SV, et al. Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). doi: 10.15829/1560-4071-2020-3-3786
- Type 2 diabetes: the management of type 2 diabetes. Clinical guideline (CG87) [Internet]. NICE. National Institute for Health and Care Excellence. Available from: http://www.nice.org.uk/guidance/cg87/resources/guidance-type-2-diabetes-pdf. Accessed: Sept 15, 2014.
- Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2012;12(4):263–277. doi: 10.1007/BF03261835
- Strauss MH, Hall AS. Angiotensin receptor blockers may increase risk of myocardial infarction. Unraveling the ARB-MI paradox. Circulation. 2006;114(8):838–854. doi: 10.1161/CIRCULATIONAHA.105.594986
- Mancia G, Rea F, Ludergnani M, et al. Renin–angiotensin–aldosterone system blockers and the risk of COVID-19. N Engl J Med. 2020;382(25):2431–2440. doi: 10.1056/NEJMoa2006923
- Mehra MR, Desai SS, Kuy SR, et al. Cardiovascular disease, drug therapy, and mortality in COVID-19. N Engl J Med. 2020;382(25):e102. doi: 10.1056/NEJMoa2007621
- Caldeira D, Alarcao J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345:e4260. doi: 10.1136/bmj.e4260
- Valsartan. Opisanie preparata v spravochnike Vidal “Lekarstvennye preparaty v Rossii” [Internet]. Мoscow, 2021. (In Russ.) Available from: https://www.vidal.ru/drugs/molecule/1107. Accessed: Dec 6, 2021.
- Losartan. Opisanie preparata v spravochnike “Lekarstvennye preparaty v Rossii” [Internet]. Мoscow, 2021. (In Russ.) Available from: https://www.vidal.ru/drugs/molecule/619. Accessed: Dec 6, 2021.
- Zheng SL, Roddick AJ, Ayis S. Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: A systematic review and meta-analysis of 13,395 patients. Diab Vasc Dis Res. 2017;14(5):400–406. doi: 10.1177/1479164117715854
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851– 860. doi: 10.1056/NEJMoa011303
- Berl T, Hunsicker LG, Lewis JB, et al. cardiovascular outcomes in the irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003;138(7):542–549. doi: 10.7326/0003-4819-138-7-200304010-00010
- Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175–1180. doi: 10.1016/j.jacc.2004.06.034
- Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ. 2004;329(7477):1248–1249. doi: 10.1136/bmj.329.7477.1248
- Strauss MH, Hall AS. Angiotensin receptor blockers do not reduce risk of myocardial infarction, cardiovascular death, or total mortality: further evidence for the ARB-MI paradox. Circulation. 2017;135(22):2088–2090. doi: 10.1161/CIRCULATIONAHA.117.026112
- Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med. 2005;165(12):1410–1419. doi: 10.1001/archinte.165.12.1410
- McDonald MA, Simpson SH, Ezekowitz JA, et al. Angiotensin receptor blockers and risk of myocardial infarction: systematic review. BMJ. 2005;331(7521):873–879. doi: 10.1136/bmj.38595.518542.3A
- Tsuyuki RT, McDonald MA. Angiotensin receptor blockers do not increase risk of myocardial infarction. Circulation. 2006;114(8):855–860. doi: 10.1161/CIRCULATIONAHA.105.594978
- Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:b1665. doi: 10.1136/bmj.b1665
- Sawada T, Yamada H, Dahlof B, et al. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J. 2009;30(20):2461–2469. doi: 10.1093/eurheartj/ehp363
- Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J. 2009;30(20):2427–2430. doi: 10.1093/eurheartj/ehp364
- Stolov SV. Inactivation of renin-angiotensin-aldosterone system. Which class of antihypertensive medicine products to prefer? Eurasian Heart Journal. 2020;(4):64–78. (In Russ.) doi: 10.38109/2225-1685-2020-4-64-78
- Papademetriou V, Farsang C, Elmfeldt D, et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175–1180. doi: 10.1016/j.jacc.2004.06.034
- Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J. 2006;152(1):86–92.
- Mochizuki S, Dahlöf B, Shimizu M, et al. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369(9571):1431–1439. doi: 10.1016/S0140-6736(07)60669-2
- Strauss MH, Lonn EM, Verma S. Is the jury out? Class specific differences on coronary outcomes with ACE-inhibitors and ARBs: insight from meta-analysis and The Blood Pressure Lowering Treatment Trialists' Collaboration. Eur Heart J. 2005;26(22):2351–2353. doi: 10.1093/eurheartj/ehi574
- Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimes based on valsartan or amlodipine: the VALUE randomized trial. Lancet. 2004;363(9426):2022–2031. doi: 10.1016/S0140-6736(04)16451-9
- GISSI AF Investigators, Disertori M, Latini R, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med. 2009;360(16):1606–1617. doi: 10.1056/NEJMoa0805710
- Al Khalaf L, Thalib SAR. Cardiovascular outcomes in high-risk patients without heart failure treated with ARBs: a systematic review and meta-analysis. Am J Cardiovasc Drugs. 2009;9(1):29–43. doi: 10.1007/BF03256593
- Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial: The Telmisartan Randomised Assessment Study in ACE intolerant subjects with cardiovascular Disease (TRANSCEND) Investigators. Lancet. 2008;372(9644):1174–1183. doi: 10.1016/S0140-6736(08)61242-8
- ONTARGET Investigators; Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–1559. doi: 10.1056/NEJMoa0801317
- Furie KL, Kasner SE, Adams RJ, et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2011;42(1):227–276. doi: 10.1161/STR.0b013e3181f7d043
- Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi: 10.1056/NEJMoa011161
- Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851–860.
- Khatib R. ACE inhibition for the prevention of myocardial infarction – 10 Seminal Papers. Dialogues in Cardiovascular Medicine. 2014;19(3):215.
- Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35(37):2541–2619. doi: 10.1093/eurheartj/ehu278
- van Vark LC, Bertrand M, Akkerhuis KM, et al. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012;33(16):2088–2097. doi: 10.1093/eurheartj/ehs075
- Collet JP, Thiele H, Barbato E, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367. doi: 10.1093/eurheartj/ehaa575
- Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159–2219. doi: 10.1093/eurheartj/eht151
- James PA, Oparil S, Carter BL, et al. 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507–520. doi: 10.1001/jama.2013.284427
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128
- Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119–177. doi: 10.1093/eurheartj/ehx393
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–3104. doi: 10.1093/eurheartj/ehy339
- Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;00:1–98.
- Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi: 10.1093/eurheartj/ehz425
- Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(27):2129–2200. doi: 10.1093/eurheartj/ehw128
- Brugts JJ, van Vark L, Akkerhuis M, et al. Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: a number-needed-to-treat analysis. Int J Cardiol. 2015;181:425–429. doi: 10.1016/j.ijcard.2014.11.179
- Go AS, Bauman MA, Coleman King SM, et al. An effective approach to high blood pressure control a science advisory from the American Heart Association, the American College of Cardiology, and the Centers for Disease Control and Prevention. Hypertension. 2014;63(4):878–885. doi: 10.1161/HYP.0000000000000003
- Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/ AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2018;71(6):1269–1324. doi: 10.1161/HYP.0000000000000066
- Kardiologiya: nacional’noe rukovodstvo. Ed. by E.V. Shlyakhto. 2-e izd. pererab. i dop. Moscow: GEHOTAR-Media; 2019. (In Russ.)
- Pilote L, Abrahamowicz M, Rodrigues E, et al. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect? Ann Intern Med. 2004;141(2):102–112. doi: 10.7326/0003-4819-141-2-200407200-00008
- Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin-converting–enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351(20):2058–2068. doi: 10.1056/NEJMoa042739
- Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin coverting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med. 2003;348(7): 583–592. doi: 10.1056/NEJMoa021716
- Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin-converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res. 2004;27(3):181–191. doi: 10.1291/hypres.27.181
Supplementary files
